Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

39.07 +1.66 (+4.44%)

Streaming Delayed Price Updated: 12:22 PM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

February 03, 2022

From UroGen Pharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 06, 2022

On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...

Via Benzinga

UroGen Pharma to Present at Upcoming Conferences

January 05, 2022

From UroGen Pharma Ltd.

Via Business Wire

First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

December 21, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

November 15, 2021

From UroGen Pharma Ltd.

Via Business Wire

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

Earnings Preview: UroGen Pharma ↗

November 12, 2021

UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Earnings Scheduled For November 15, 2021 ↗

November 15, 2021

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

UroGen Pharma Announces Upcoming 2021 Conferences

November 11, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

November 10, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021

November 01, 2021

From UroGen Pharma Ltd.

Via Business Wire

The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

October 05, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 23, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting

September 13, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 10, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 03, 2021

From UroGen Pharma Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

August 20, 2021

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

August 19, 2021

Thursday morning, 173 companies reached new 52-week lows. Areas of Interest: The largest company by market cap to set a new 52-week low was Alibaba Group Holding (...

Via Benzinga

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

August 04, 2021

From UroGen Pharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings ↗

August 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Earnings Scheduled For August 4, 2021 ↗

August 04, 2021

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter. • Vericel (NASDAQ:VCEL) is expected to...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

July 28, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021

July 28, 2021

From UroGen Pharma Ltd.

Via Business Wire

UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021

July 14, 2021

From UroGen Pharma Ltd.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.